Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Total Current Liabilities (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Total Current Liabilities for 11 consecutive years, with $14.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Current Liabilities fell 34.99% to $14.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $14.9 million, a 34.99% decrease, with the full-year FY2025 number at $14.9 million, down 34.99% from a year prior.
  • Total Current Liabilities was $14.9 million for Q4 2025 at Cartesian Therapeutics, up from $13.8 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $95.6 million in Q3 2021 to a low of $12.3 million in Q2 2025.
  • A 5-year average of $38.4 million and a median of $26.3 million in 2023 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: surged 287.81% in 2021, then plummeted 75.18% in 2022.
  • Cartesian Therapeutics' Total Current Liabilities stood at $72.3 million in 2021, then crashed by 65.29% to $25.1 million in 2022, then skyrocketed by 172.0% to $68.2 million in 2023, then plummeted by 66.32% to $23.0 million in 2024, then plummeted by 34.99% to $14.9 million in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Total Current Liabilities are $14.9 million (Q4 2025), $13.8 million (Q3 2025), and $12.3 million (Q2 2025).